Genevant Sciences GmbH

Rule Changes

Settlement plaintiff; receives 80% of proceeds; co-plaintiff in Pfizer/BioNTech case

For four years, Moderna faced questions about whether it owed billions for technology at the heart of its COVID-19 vaccine. Less than a week before a jury trial in Delaware, Moderna agreed to pay $2.25 billion to settle patent claims from Arbutus Biopharma and Genevant Sciences. The court found it infringed four valid patents, and if paid in full, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated May 30